GI Hepatobiliary

Hepatocellular Carcinoma

Localized

No Prior Therapy

IRB# 20744 Pembrolizumab + Lenvatinib + TACE (Transarterial Chemoembolization) vs Placebo + TACE in Intermediate Stage HCC

IRB# 23365 A Phase II Study to Evaluate the Efficacy and Safety of Y-90, Atezolizumab and Cabozantinib Among Patients with unresectable and locally-advanced HCC

Prior Therapy

1st Line

IRB# 20929 Phase II study of TSR-022 (COBOLIMAB) in combination with TSR-042 (DOSTARILIMAB) for the treatment of advanced hepatocellular carcinoma

2nd Line

No Trials Currently Available

IRB# 20357 [NCI CIRB] A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

IRB# 16033 Phase II study of induction systemic mFOLFIRINOX followed by hepatic arterial infusion of Floxuridine and Dexamethasone given concurrently with systemic mFOLFIRI as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma

IRB# 24798 A Phase 1/1b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants with Advanced Tumors Harboring FGFR2 and FGFR3 Gene Alterations

Cholangiocarcinoma

1st Line

No Trials Currently Available

1st or 2nd Line

2nd Line or more

CROSS-DISEASE TRIALS:

IRB# TBD EAY131 (MATCH)

KEY

Open to Enrollment
In Development
Enrollment on Hold

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result
IRB# 23005
EA2197, Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result